Crossmark

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients

Crossref DOI link: https://doi.org/10.1007/s10637-016-0385-0

Published Online: 2016-08-24

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Di Desidero, Teresa

Derosa, Lisa

Galli, Luca

Orlandi, Paola

Fontana, Andrea

Fioravanti, Anna

Marconcini, Riccardo

Giorgi, Mario

Campi, Beatrice

Saba, Alessandro

Lucchesi, Sara

Felipetto, Renato

Danesi, Romano

Francia, Giulio

Allegrini, Giacomo

Falcone, Alfredo

Bocci, Guido
Funding

Funding for this research was provided by:

Associazione Italiana per la Ricerca sul Cancro
License Information

Text and Data Mining valid from 2016-08-24

Version of Record valid from 2016-08-24
More Information

Article History

Received: 10 August 2016

Accepted: 18 August 2016

First Online: 24 August 2016

Compliance with ethical standards

:

: All the authors declare that they have no conflict of interest.

: The present work was supported, in part, by the Italian Association for Cancer Research to GB.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below